Dongcheng Pharmaceutical announced that the holding subsidiary Zhongtai Biotech underwent on-site inspections by the US Food and Drug Administration from July 17 to July 18, 2026. Recently, it received an on-site inspection report issued by the FDA and passed the on-site inspection with zero “483” NAI defects.

Zhitongcaijing · 2d ago
Dongcheng Pharmaceutical announced that the holding subsidiary Zhongtai Biotech underwent on-site inspections by the US Food and Drug Administration from July 17 to July 18, 2026. Recently, it received an on-site inspection report issued by the FDA and passed the on-site inspection with zero “483” NAI defects.